Tandem Diabetes Care, Inc.
看多
已更新

Tandem is oversold going into ER month

264
The recent analyst day was great, in my opinion, with strong product pipeline which should be followed by strong delivery. Guidance is up and most likely conservative going into next month's earnings call. Short term headwinds with regards to overbought status should dissipate soon as Tandem is far from being overbought. It has a strong chance of becoming a market leader a few years down the road, especially with international expansion. Control-IQ and t:sport will propel the stock to new highs.
交易結束:達到停損點

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。